Mode
Text Size
Log in / Sign up

Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer

Share
Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
Photo by Bagoes Ilhamy / Unsplash

This post hoc analysis looked at a Phase III randomized controlled trial involving 329 patients with high-risk prostate cancer. The researchers compared intensity-modulated radiotherapy (IMRT) against three-dimensional conformal radiotherapy (3D-CRT) using androgen suppression. Because this was a post hoc analysis, the results should be interpreted with caution. The study included 296 patients in the final comparison.

The main findings showed that IMRT reduced the risk of severe acute and delayed gastrointestinal and genitourinary toxicities compared to 3D-CRT. However, IMRT did increase the risk of mild acute genitourinary toxicities. There were no significant differences between the two techniques regarding biochemical failure-free survival, distant metastasis-free survival, or overall survival.

The study notes that high-risk prostate cancer patients receiving external beam radiation often get IMRT as a standard treatment. This analysis suggests IMRT may be the preferred technique. Readers should remember this is a post hoc analysis, which limits the certainty of the findings. The study also lists non-randomized comparison as a limitation. Always discuss treatment options with a healthcare provider.

What this means for you:
Post hoc analysis suggests IMRT reduces severe radiation side effects but increases mild ones for high-risk prostate cancer.
Share
More on high-risk localized prostate cancer